These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16440753)

  • 1. [Construction history of bispecific antibodies and overview of its application for cancer immunotherapy].
    Asano R
    Seikagaku; 2005 Dec; 77(12):1497-501. PubMed ID: 16440753
    [No Abstract]   [Full Text] [Related]  

  • 2. Recombinant bispecific antibodies for cancer therapy.
    Kontermann RE
    Acta Pharmacol Sin; 2005 Jan; 26(1):1-9. PubMed ID: 15659107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific antibodies for cancer therapy.
    Chames P; Baty D
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):276-83. PubMed ID: 19333873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant bispecific antibodies for cellular cancer immunotherapy.
    Müller D; Kontermann RE
    Curr Opin Mol Ther; 2007 Aug; 9(4):319-26. PubMed ID: 17694444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific antibodies for cancer therapy.
    Hollander N
    Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bispecific antibodies, novel therapeutic candidates harnessing the immune system].
    Chames P; Wurch T
    Med Sci (Paris); 2019 Dec; 35(12):1072-1082. PubMed ID: 31903920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current perspectives of bispecific antibody-based immunotherapy.
    Talac R; Nelson H
    J Biol Regul Homeost Agents; 2000; 14(3):175-81. PubMed ID: 11037049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific antibodies for cancer immunotherapy: Current perspectives.
    Müller D; Kontermann RE
    BioDrugs; 2010 Apr; 24(2):89-98. PubMed ID: 20199124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bi-specific antibody therapy for the treatment of cancer.
    Withoff S; Helfrich W; de Leij LF; Molema G
    Curr Opin Mol Ther; 2001 Feb; 3(1):53-62. PubMed ID: 11249732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific antibodies in cancer immunotherapy.
    Chen S; Li J; Li Q; Wang Z
    Hum Vaccin Immunother; 2016 Oct; 12(10):2491-2500. PubMed ID: 27249163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the generation of bispecific antibodies for tumor immunotherapy.
    Kipriyanov SM; Le Gall F
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):233-42. PubMed ID: 15603258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative molecular formats and therapeutic applications for bispecific antibodies.
    Spiess C; Zhai Q; Carter PJ
    Mol Immunol; 2015 Oct; 67(2 Pt A):95-106. PubMed ID: 25637431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic antibodies and antibody fusion proteins.
    Rohrbach P; Broders O; Toleikis L; Dübel S
    Biotechnol Genet Eng Rev; 2003; 20():137-63. PubMed ID: 14997850
    [No Abstract]   [Full Text] [Related]  

  • 14. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
    Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
    Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific antibodies in cancer therapy.
    Segal DM; Weiner GJ; Weiner LM
    Curr Opin Immunol; 1999 Oct; 11(5):558-62. PubMed ID: 10508714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.
    Yang F; Wen W; Qin W
    Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28036020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Research evolutions in immuno-oncology and their impact on the management of patients treated with immunotherapy].
    Caux C
    Bull Cancer; 2020 Jan; 107(1):6-9. PubMed ID: 31954504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A revival of bispecific antibodies.
    Kufer P; Lutterbüse R; Baeuerle PA
    Trends Biotechnol; 2004 May; 22(5):238-44. PubMed ID: 15109810
    [No Abstract]   [Full Text] [Related]  

  • 19. Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology.
    Suzuki M; Curran KJ; Cheung NK
    Pediatr Blood Cancer; 2015 Aug; 62(8):1326-36. PubMed ID: 25832831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors.
    Satta A; Mezzanzanica D; Turatti F; Canevari S; Figini M
    Future Oncol; 2013 Apr; 9(4):527-39. PubMed ID: 23560375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.